Digital therapeutics (DTx) are defined as high-quality software designed to prevent, manage, and treat medicaldisorders or diseases by providing evidence-based therapeutic interventions. In this study, an investigation was conducted to examine the characteristics of DTx, including their methods, safety-related data, and user evaluations of reSET®, reSET-O®, and Somryst®. These DTx solutions have recently obtained the first FDA approval and the first insurance code registration by government. However, there are limitations in terms of the quantitative scale of patient feedback evaluations and concerns about accuracy, as indicated by research findings. Nevertheless, with the active global development of DTx and the increasing scale of investment, pharmacists need to pay attention to and prepare for this innovative treatment concept.